Trial Profile

A First-in-human, Open-label Dose Escalation Followed by Dose Expansion Phase I/IIa Trial to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of Intratumoral CyPep-1 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Cancers

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CyPep-1 (Primary) ; Pembrolizumab (Primary)
Indications Advanced breast cancer; Head and neck cancer; Lymphoma; Malignant melanoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; First in man
Acronyms CICILIA
Sponsors Cytovation

13 Sep 2024 Results published in a Cytovation media release
13 Sep 2024 According to a Cytovation media release, company will deliver a poster presentation at ESMO 2024 from this Phase I/IIa CICILIA trial.
24 Jul 2024 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com